Goldman Sachs reinstated coverage of 4D Molecular with a Buy rating and $81 price target. The analyst cites the positive Phase 2 intravitreal gene therapy 4D-150 data in wet age-related macular degeneration and the planned Phase 3 initiation in Q1 of 2025 for the Buy rating. The firm believes 4D’s current valuation overlooks the readthrough to the company’s directed evolution-based platform across three disease verticals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FDMT:
- 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- 4D Molecular files automatic mixed securities shelf
- 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
- 4D Molecular announces $250M common stock offering
- 4D Molecular files to sell $250M in common stock
